Vincent Capponi - 04 Oct 2024 Form 4 Insider Report for Cytosorbents Corp (CTSO)

Role: President and COO
Signature: /s/ Vincent Capponi
Issuer symbol: CTSO
Transactions as of: 04 Oct 2024
Net transactions value: $0
Form type: 4
Filing time: 08 Oct 2024, 21:00:14 UTC
Previous filing: 04 Apr 2024
Next filing: 22 Jan 2025
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CTSO	Stock Option (Right to Buy)	Award		+100,000			100,000	04 Oct 2024	Common Stock	100,000	$1.19	Direct	F1
transaction	CTSO	Stock Option (Right to Buy)	Award		+50,000			50,000	04 Oct 2024	Common Stock	50,000	$1.19	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These stock options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"). The shares underlying these stock options will vest immediately upon the Company's achievement of U.S. Food and Drug Administration clearance or approval of DrugSorb-ATR, subject to the Company's receipt of such clearance or approval prior to June 30, 2026 and the reporting person's continued service as of the applicable vesting date.
F2	These stock options were granted pursuant to the Plan. The shares underlying these stock options will vest immediately upon the Company's achievement of Health Canada clearance or approval of DrugSorb-ATR before, subject to the Company's receipt of such clearance or approval prior to June 30, 2026 and the reporting person's continued service as of the applicable vesting date.

Content

These stock options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"). The shares underlying these stock options will vest immediately upon the Company's achievement of U.S. Food and Drug Administration clearance or approval of DrugSorb-ATR, subject to the Company's receipt of such clearance or approval prior to June 30, 2026 and the reporting person's continued service as of the applicable vesting date.

These stock options were granted pursuant to the Plan. The shares underlying these stock options will vest immediately upon the Company's achievement of Health Canada clearance or approval of DrugSorb-ATR before, subject to the Company's receipt of such clearance or approval prior to June 30, 2026 and the reporting person's continued service as of the applicable vesting date.